


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:34Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406995" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406995</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JCO Clin Cancer Inform</journal-id><journal-id journal-id-type="iso-abbrev">JCO Clin Cancer Inform</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">CCI</journal-id><journal-title-group><journal-title>JCO Clinical Cancer Informatics</journal-title></journal-title-group><issn pub-type="epub">2473-4276</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406995</article-id><article-id pub-id-type="pmcid-ver">PMC12406995.1</article-id><article-id pub-id-type="pmcaid">12406995</article-id><article-id pub-id-type="pmcaiid">12406995</article-id><article-id pub-id-type="pmid">40854169</article-id><article-id pub-id-type="doi">10.1200/CCI-25-00105</article-id><article-id pub-id-type="publisher-id">CCI-25-00105</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>ORIGINAL REPORTS</subject><subj-group><subject>Artificial Intelligence</subject></subj-group></subj-group></article-categories><title-group><article-title>Machine Learning Model Integrating Computed Tomography Image&#8211;Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9575-8214</contrib-id><name name-style="western"><surname>Ozgun</surname><given-names initials="G">Guliz</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdalvand</surname><given-names initials="N">Neda</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con1" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ozcan</surname><given-names initials="G">Gizem</given-names></name><degrees>MSc</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-9482-7058</contrib-id><name name-style="western"><surname>Nip</surname><given-names initials="KM">Ka Mun</given-names></name><degrees>MSc</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khazamipour</surname><given-names initials="N">Nastaran</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9980-2403</contrib-id><name name-style="western"><surname>Rahmim</surname><given-names initials="A">Arman</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con2" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2456-0972</contrib-id><name name-style="western"><surname>Bell</surname><given-names initials="R">Robert</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>MauriceDror</surname><given-names initials="C">Corinne</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soleimani</surname><given-names initials="M">Maryam</given-names></name><degrees>MD, MSc</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chi</surname><given-names initials="K">Kim</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eigl</surname><given-names initials="BJ">Bernhard J.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6256-1511</contrib-id><name name-style="western"><surname>Nichols</surname><given-names initials="C">Craig</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6329-761X</contrib-id><name name-style="western"><surname>Kollmannsberger</surname><given-names initials="C">Christian</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="con3" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5127-7841</contrib-id><name name-style="western"><surname>Yuan</surname><given-names initials="R">Ren</given-names></name><degrees>MD, PhD</degrees><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4365-7251</contrib-id><name name-style="western"><surname>Nappi</surname><given-names initials="L">Lucia</given-names></name><degrees>MD, PhDzax</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1" ref-type="corresp"/><xref rid="con4" ref-type="fn"/></contrib><aff id="aff1"><label><sup>1</sup></label>BC Cancer Vancouver Center, Department of Medical Oncology, Vancouver, BC, <country>Canada</country></aff><aff id="aff2"><label><sup>2</sup></label>BC Cancer Research Center, Vancouver, BC, <country>Canada</country></aff><aff id="aff3"><label><sup>3</sup></label>Vancouver Prostate Centre, Vancouver, BC, <country>Canada</country></aff><aff id="aff4"><label><sup>4</sup></label>Testicular Cancer Commons, Beaverton, OR</aff><aff id="aff5"><label><sup>5</sup></label>BC Cancer Vancouver Center, Department of Radiology, Vancouver, BC, <country>Canada</country></aff></contrib-group><author-notes><corresp id="cor1">Lucia Nappi, MD, PhD; Social Media Handle: @lucianappi4; e-mail: <email>lucia.nappi@bccancer.bc.ca</email>.</corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>8</month><year>2025</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">496166</issue-id><elocation-id>e2500105</elocation-id><history><date date-type="received"><day>8</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>19</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by American Society of Clinical Oncology</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>American Society of Clinical Oncology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensed under the Creative Commons Attribution 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="cci-9-e2500105.pdf"/><self-uri xlink:href="cci-9-e2500105.pdf"/><abstract><sec><title>PURPOSE</title><p>Chemotherapy is the primary treatment for metastatic nonseminomatous germ cell tumors (mNSGCTs), but patients often encounter postchemotherapy residual disease. Accurate noninvasive methods are needed to predict the histology of these masses, guiding treatment and reserving surgery for those with teratoma. This study aims to enhance predictive accuracy by integrating computed tomography (CT) radiomics features with miRNAs (miR371-375) to distinguish between teratoma and nonteratoma histology in postchemotherapy residual masses.</p></sec><sec><title>METHODS</title><p>We retrospectively identified 111 lesions, divided into training and test sets (n = 78 <italic toggle="yes">v</italic> 33) with equal class distribution. 3D Slicer was used to segment lesions with a short axis of &gt;10 mm from the postchemo-presurgical CT images, and radiomics features were extracted. Presurgery plasma miR371-375 levels were measured by real-time polymerase chain reaction. Four machine learning models evaluated the predictive value of radiomics alone (R-only) and combined with miR371-375 levels, and the best performer was selected. Clinical factors associated with teratoma from univariate analysis were included in multivariate analysis with the best radiomics signature to assess their impact on predicting teratoma histology.</p></sec><sec><title>RESULTS</title><p>The CatBoost (CB) model R + 371 + 375 exhibited the best and most robust overall accuracy for predicting residual teratoma, with the highest AUC values (0.96, 95% CI, 0.88 to 1.0 for training, 0.83, 95% CI, 0.68 to 0.98 for testing) and a well-balanced sensitivity and specificity. Univariate analysis identified presurgery alpha-fetoprotein (<italic toggle="yes">P</italic> = .01), beta-human chorionic gonadotropin (<italic toggle="yes">P</italic> = .01), initial teratoma pathology (<italic toggle="yes">P</italic> = .01), and lymph node metastases (<italic toggle="yes">P</italic> = .02) as significant predictors for teratoma. Multivariate analysis included these features and the radiomics signature, which was the strongest independent predictor (<italic toggle="yes">P</italic> &lt; .0001).</p></sec><sec><title>CONCLUSION</title><p>Combining miR371-375 with CT radiomics features improves the accuracy of predicting teratoma histology of postchemotherapy residual disease in mNSGCTs and, therefore, has the potential to guide treatment decision making.</p></sec></abstract><counts><fig-count count="3"/><table-count count="3"/><equation-count count="0"/><ref-count count="54"/><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction"><title>INTRODUCTION</title><p>Testicular cancer is classified into two main histological subtypes, seminoma and nonseminoma (including embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma, mixed together or sometimes with seminoma histology), and is the most common solid tumor in young men age 15-45 years.<sup><xref rid="b1" ref-type="bibr">1</xref>-<xref rid="b3" ref-type="bibr">3</xref></sup> Testicular cancer also shows molecular heterogeneity among the various histology subtypes: embryonal carcinomas often overexpress pluripotency-related gene while teratomas express genes related to somatic differentiation.<sup><xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b5" ref-type="bibr">5</xref></sup> As an example, AGR2 and KRT19 proteins and their related genes were recently shown to be differently expressed between teratoma and benign tissue in the postchemotherapy resection material.<sup><xref rid="b6" ref-type="bibr">6</xref></sup> Fortunately, regardless of the subtype, testicular cancer can be effectively treated with chemotherapy, often in conjunction with surgery or radiation therapy. Patients with mNSGCT often have residual disease after chemotherapy, and resection of any residual mass measuring over 10 mm is recommended because of the risk of growing teratoma syndrome and malignant somatic transformation of residual teratomas, both characterized by poor response to chemotherapy and limited treatment options.<sup><xref rid="b7" ref-type="bibr">7</xref>-<xref rid="b9" ref-type="bibr">9</xref></sup> However, the current treatment approaches to address the possible residual teratoma can lead to overtreatment and thus unnecessary complications, as benign lesions such as fibrosis are identified in about 50% of patients, while teratoma and viable germ cell tumors (vGCTs) are identified in 40% and 15% of patients, respectively.<sup><xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref></sup> Therefore, accurate histology prediction models are needed to guide patient selection for different treatment strategies.</p><boxed-text id="B1" position="anchor" orientation="portrait"><sec sec-type="context-box"><title>CONTEXT</title><p>
<list list-type="simple"><list-item><p>
<bold>Key Objective</bold>
</p></list-item><list-item><p>Can the integration of radiomics and microRNAs data enhance the accuracy of histological prediction of postchemotherapy residual disease in metastatic nonseminomatous germ cell tumors (mNSGCTs)?</p></list-item><list-item><p>
<bold>Knowledge Generated</bold>
</p></list-item><list-item><p>This study demonstrates that integrating computed tomography radiomics features with circulating miR371 and miR375 provides a powerful approach to distinguish teratoma from nonteratoma histology in mNSGCT patients with postchemotherapy residual disease. The combined model achieved strong predictive performance, outperforming clinical parameters alone, and represents a promising step toward more personalized and precise treatment planning in testicular cancer care.</p></list-item><list-item><p>
<bold>Relevance <italic toggle="yes">(J. Warner)</italic></bold>
</p></list-item><list-item><p>This predictive model built on readily acquired clinical data provides encouraging results for the detection of residual disease. External validation and prospective studies implementing the model in a clinical decision-making pathway should be considered next.*</p></list-item><list-item><p>*Relevance section written by <italic toggle="yes">JCO CCI</italic> Editor-in-Chief Jeremy Warner, MD, MS, FAMIA, FASCO.</p></list-item></list>
</p></sec></boxed-text><p>Computed tomography (CT) and magnetic resonance imaging cannot predict the histology of the residual disease after chemotherapy. Fluorodeoxyglucose (FDG)-positron emission tomography-CT offers limited utility in mNSGCTs, especially when the lesions have intermediate FDG uptake.<sup><xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b13" ref-type="bibr">13</xref></sup> Biopsy of the residual lesions is invasive, could have sample bias, and is not always feasible. To address these limitations, ongoing efforts aim to integrate artificial intelligence (AI) for pattern recognition and quantitative analysis of medical images with biomarkers to improve diagnostic accuracy.</p><p>Radiomics is a developing field of quantitative imaging, converting medical images to mineable data.<sup><xref rid="b14" ref-type="bibr">14</xref>-<xref rid="b16" ref-type="bibr">16</xref></sup> So far, radiomics has been shown to be a valuable tool for predicting histology, treatment response, and prognosis.<sup><xref rid="b17" ref-type="bibr">17</xref>-<xref rid="b21" ref-type="bibr">21</xref></sup> In mNSGCTs, radiomics presented promising results in predicting malignant retroperitoneal lymph nodes (RPLN).<sup><xref rid="b22" ref-type="bibr">22</xref>-<xref rid="b24" ref-type="bibr">24</xref></sup> These studies have primarily focused on the radiomics-only approach to discriminate malignant (vGCT + teratoma) versus benign lesions. However, the most relevant and still unmet clinical need is determining the teratoma component that requires surgery to be eradicated.<sup><xref rid="b8" ref-type="bibr">8</xref></sup></p><p>Studies on novel circulating biomarkers, such as miRNAs 371-373 and 302/367 clusters, have been conducted in testicular GCTs.<sup><xref rid="b25" ref-type="bibr">25</xref></sup> Among these, miRNA-371a-3p (miR371) has shown the highest accuracy in detecting vGCTs.<sup><xref rid="b26" ref-type="bibr">26</xref>,<xref rid="b27" ref-type="bibr">27</xref></sup> Thus, large prospective clinical trials, such as the SWOG S1823 and the COG 1531, were set up, aiming to validate miR371 to predict tumor relapse in patients with early-stage GCTs.<sup><xref rid="b28" ref-type="bibr">28</xref>,<xref rid="b29" ref-type="bibr">29</xref></sup> Despite encouraging results, miR371 is unable to detect teratoma. Another microRNA, miR375, has shown higher expression in teratoma than in other vGCTs. Combining miR371 and miR375 to differentiate GCT histologic subtypes has improved accuracy, yet it is suboptimal to be proposed as a clinical tool.<sup><xref rid="b30" ref-type="bibr">30</xref></sup></p><p>Recently, given the limited efficacy of single-omics data, there has been a growing interest in combining different approaches to enhance accuracy.<sup><xref rid="b31" ref-type="bibr">31</xref></sup> Within this context, integrating radiomics with biomarkers such as miRNAs to predict teratoma histology remains underexplored, necessitating further studies to establish clinical utility. Built on our previous work<sup><xref rid="b30" ref-type="bibr">30</xref></sup> and the potentially promising role of radiomics in medical imaging, we hypothesize that integrating CT-driven radiomics features with miR371 and miR375 may enhance the predictive accuracy in identifying teratoma in mNSGCT patients with postchemotherapy residual masses to accurately select patients for surgery.</p></sec><sec sec-type="methods"><title>METHODS</title><sec sec-type="subjects"><title>Patient Selection Criteria</title><p>The study was approved by the University of British Columbia Ethical Board (H18-01484). A retrospective data set from the British Columbia Cancer GU biobank was compiled that satisfied the following eligibility criteria: males who were diagnosed with mNSGCT and had residual disease larger than 10 mm (ie, residual masses over 10 mm in diameter and lymph nodes over 10 mm short axis) after cisplatin-based chemotherapy, with normal serum tumor markers before surgical resection (alpha-fetoprotein [AFP]: &lt;8.4 &#181;g/L and beta-human chorionic gonadotropin (&#946;-hCG): &lt;3 IU/L) and underwent surgical resection of residual disease, with available presurgical blood samples and CT scan and pathology reports of the resected lesions. Patients were excluded if their presurgical CT did not have intravenous contrast, had poor imaging quality, or the residual masses had not been adequately assessed (Fig <xref rid="fig1" ref-type="fig">1</xref>). Seminoma cases with available presurgery blood samples were included for AI training purposes.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>FIG 1.</label><caption><p>The flow diagram illustrating the participants enrolled in the study. <sup>a</sup>Seminoma cases with available pre-surgery blood samples were included for AI training purposes. AFP, alpha-fetoprotein; &#946;-hCG, beta-human chorionic gonadotropin; CT, computed tomography; GCT, germ cell tumor; mGCT, metastatic germ cell tumor; mNSGCT, metastatic nonseminomatous GCT; ROI, region of interest.</p></caption><graphic position="float" orientation="portrait" xlink:href="cci-9-e2500105-g001.jpg"/></fig></sec><sec><title>Radiomics Signature Design</title><p>Residual lesions were identified on the CT images by two independent investigators (R.Y. and G.O.) who also reviewed the CT reports and correlated the CT images with the surgical pathology. After this extensive review, the residual lesions were labeled as teratoma or nonteratoma.</p><p>3D Slicer (version 5.6.1)<sup><xref rid="b32" ref-type="bibr">32</xref></sup> was used to manually segment regions of interest (ROIs) corresponding to residual masses with diameter &#8805;10 mm (or short axis &#8805;10 mm in lymph nodes; Data Supplement, Fig S1). Radiomics features were extracted using the Radiomics extension in 3D Slicer, which is based on the PyRadiomics library.</p><p>We used LassoCV for feature selection, shrinking less significant features' coefficients to zero. After identifying the most relevant radiomics features and defining radiomics signatures, machine learning (ML) models were developed and subjected to comprehensive evaluation to determine the best-performing model for accurate teratoma histology prediction (Fig <xref rid="fig2" ref-type="fig">2</xref>).</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>FIG 2.</label><caption><p>Schematic diagram of the study roadmap. The workflow starts with image acquisition, segmentation, and feature extraction. Features are selected, and ML models are developed. The most effective model is determined through evaluation, while radiomics signatures are calculated separately. CV, cross-validation; ML, machine learning.</p></caption><graphic position="float" orientation="portrait" xlink:href="cci-9-e2500105-g002.jpg"/></fig><p>Radiomics (R) features were integrated with miR371-375 (371 and 375) in different combinations, creating four separate data sets: R, R + 371, R + 375, and R + 371 + 375.</p></sec><sec><title>Classifier Construction</title><p>Four commonly used feature selection algorithms were used to identify discriminating features: CatBoost (CB), Random Forest (RF), Gradient Boosting (GB), and Support Vector Machine (SVM). Each has distinct strengths with the specific data set construction in this study.<sup><xref rid="b33" ref-type="bibr">33</xref>-<xref rid="b36" ref-type="bibr">36</xref></sup> After the evaluation of four ML models, the best ML model, CB was selected because of its superior performance. We implemented nested cross-validation (CV) using stratified 10-fold CV to achieve robust model evaluation.</p></sec><sec><title>miRNA Analysis: RNA Extraction and Real-Time Polymerase Chain Reaction Analysis</title><p>The miRNA analysis was conducted in line with the methodology established in our previous works.<sup><xref rid="b30" ref-type="bibr">30</xref>,<xref rid="b37" ref-type="bibr">37</xref></sup> Blood samples were obtained from the British Columbia Cancer GU biobank under standardized collection and processing protocols within 8-12 weeks of treatment initiation.</p><p>Detailed methodology is included in the Data Supplement.</p></sec><sec><title>Statistical Analysis</title><p>All data were entered into an Excel spreadsheet securely stored on our local, password-protected BC Cancer server. The data were deidentified before conducting statistical analysis. Descriptive statistics was used to describe the patient characteristics.</p><p>Seventy-eight samples (39 teratomas and 39 nonteratomas) were allocated to the training set, and 33 (17 teratomas and 16 nonteratomas) were added to the test set, maintaining equal class distribution in both sets. The training set was used for feature selection and model development, while the test set remained completely unseen during training.</p><p>Model performances were evaluated on the training and unseen test sets using receiver operating characteristic (ROC) curves, with the AUC as the primary performance metric. Confidence intervals for the AUC values are computed through bootstrap sampling with 1,000 iterations, enabling the assessment of variability in model performance. Additionally, sensitivity (SN), specificity (SP), positive predictive value (PPV), and negative predictive value (NPV) are reported.</p><p>To assess whether the sample mean significantly differs from the population mean, a Z-test was conducted (Data Supplement, Table S2). The model with the highest AUC was identified to determine the best-performing approach.</p><p>Univariate analysis was conducted to investigate the predictive value of clinical factors (ie, teratoma histology in the primary, prechemotherapy tumor markers&#8212;AFP, &#946;-hCG, and lactate dehydrogenase&#8211;, lesion size, and lesion location).<sup><xref rid="b38" ref-type="bibr">38</xref></sup> Finally, a multivariate analysis was used to determine the independent impact on teratoma prediction. Statistical significance was defined as two-tailed <italic toggle="yes">P</italic> &lt; .05 for all tests.</p><p>This study was approved by the University of British Columbia Ethical Board (H18-01484). Informed consent from each participant or each participant's guardian was obtained before enrolling the patients in the research study.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec sec-type="subjects"><title>Patients and Sample Characteristics</title><p>On the basis of the inclusion criteria, 52 patients were identified, with a median age of 33 years (IQR, 23-66). These patients contributed a total of 111 lesions, including teratoma (n = 56), fibrosis/necrosis (n = 34), vGCT (n = 11), and seminoma lesions (n = 10). The lesions were distributed across various sites: 87 lymph nodes (n = 68 in the retroperitoneum, n = 11 in the mediastinum, n = 4 in the pelvic region, and n = 4 in the neck), lung (n = 21), and brain (n = 3). The median lesion size was 20 mm (15-32 mm) longitudinally and 27 mm (16-40 mm) transversely, with an interquartile range of 12-27.3 mm (Table <xref rid="tbl1" ref-type="table">1</xref>).</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>TABLE 1.</label><caption><p>Characterization of Patients and Lesions Included in the Study</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Total Population</th><th align="center" rowspan="1" colspan="1">Necrosis/Fibrosis</th><th align="center" rowspan="1" colspan="1">Teratoma</th><th align="center" rowspan="1" colspan="1">vGCT and Seminoma</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Patient population, No.</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td rowspan="1" colspan="1">Residual masses, No.</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">56</td><td align="char" char="(" rowspan="1" colspan="1">21 (11 + 10)</td></tr><tr><td rowspan="1" colspan="1">Age at diagnosis, years, median (IQR)</td><td align="char" char="(" rowspan="1" colspan="1">33 (23-66)</td><td align="char" char="(" rowspan="1" colspan="1">32 (27-66)</td><td align="char" char="(" rowspan="1" colspan="1">28 (20-47)</td><td align="char" char="(" rowspan="1" colspan="1">33 (23-56)</td></tr><tr><td rowspan="1" colspan="1">Longitudinal size of lesion (diameter, in mm)</td><td align="char" char="(" rowspan="1" colspan="1">20 (15-32)</td><td align="char" char="(" rowspan="1" colspan="1">16 (14-23)</td><td align="char" char="(" rowspan="1" colspan="1">27 (16-40)</td><td align="char" char="(" rowspan="1" colspan="1">18 (15-25)</td></tr><tr><td rowspan="1" colspan="1">Transverse size of lesion (diameter, in mm)</td><td align="char" char="(" rowspan="1" colspan="1">27 (16-40)</td><td align="char" char="(" rowspan="1" colspan="1">20 (15-29)</td><td align="char" char="(" rowspan="1" colspan="1">33 (19-45)</td><td align="char" char="(" rowspan="1" colspan="1">24 (20-33)</td></tr><tr><td colspan="5" rowspan="1">Presence of histologies in the primary tumor, No. (%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Teratoma</td><td align="char" char="(" rowspan="1" colspan="1">51 (45.9)</td><td align="char" char="(" rowspan="1" colspan="1">10 (19.6)</td><td align="char" char="(" rowspan="1" colspan="1">33 (64.76)</td><td align="char" char="(" rowspan="1" colspan="1">8 (15.6)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Seminoma</td><td align="char" char="(" rowspan="1" colspan="1">43 (38.7)</td><td align="char" char="(" rowspan="1" colspan="1">8 (18.6)</td><td align="char" char="(" rowspan="1" colspan="1">23 (53.48)</td><td align="char" char="(" rowspan="1" colspan="1">12 (27.9)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Yolk sac</td><td align="char" char="(" rowspan="1" colspan="1">50 (45)</td><td align="char" char="(" rowspan="1" colspan="1">17 (34)</td><td align="char" char="(" rowspan="1" colspan="1">28 (56)</td><td align="char" char="(" rowspan="1" colspan="1">5 (10)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Embryonal carcinoma</td><td align="char" char="(" rowspan="1" colspan="1">45 (40.5)</td><td align="char" char="(" rowspan="1" colspan="1">11 (24.4)</td><td align="char" char="(" rowspan="1" colspan="1">31 (68.8)</td><td align="char" char="(" rowspan="1" colspan="1">3 (6.66)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Choriocarcinoma</td><td align="char" char="(" rowspan="1" colspan="1">13 (11.7)</td><td align="char" char="(" rowspan="1" colspan="1">7 (53.8)</td><td align="char" char="(" rowspan="1" colspan="1">3 (23.07)</td><td align="char" char="(" rowspan="1" colspan="1">3 (23.07)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Unknown</td><td align="char" char="(" rowspan="1" colspan="1">18 (16.2)</td><td align="char" char="(" rowspan="1" colspan="1">14 (77.77)</td><td align="char" char="(" rowspan="1" colspan="1">2 (11.11)</td><td align="char" char="(" rowspan="1" colspan="1">2 (11.11)</td></tr><tr><td colspan="5" rowspan="1">Anatomic locations, No. (%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Lymph nodes</td><td align="char" char="(" rowspan="1" colspan="1">87 (78.38)</td><td align="char" char="(" rowspan="1" colspan="1">20(59)</td><td align="char" char="(" rowspan="1" colspan="1">49 (87.5)</td><td align="char" char="(" rowspan="1" colspan="1">18 (85.71)</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Retroperitoneum</td><td align="char" char="(" rowspan="1" colspan="1">68 (61.26)</td><td align="char" char="(" rowspan="1" colspan="1">17 (50)</td><td align="char" char="(" rowspan="1" colspan="1">35 (62.5)</td><td align="char" char="(" rowspan="1" colspan="1">16 (76.19)</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Pelvis</td><td align="char" char="(" rowspan="1" colspan="1">4 (3.6)</td><td align="char" char="(" rowspan="1" colspan="1">1 (2.94)</td><td align="char" char="(" rowspan="1" colspan="1">3 (5.36)</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Mediastinum</td><td align="char" char="(" rowspan="1" colspan="1">11 (9.91)</td><td align="char" char="(" rowspan="1" colspan="1">2 (5.88)</td><td align="char" char="(" rowspan="1" colspan="1">8 (14.29)</td><td align="char" char="(" rowspan="1" colspan="1">1 (4.76)</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Neck</td><td align="char" char="(" rowspan="1" colspan="1">4 (3.6)</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="char" char="(" rowspan="1" colspan="1">3 (5.36)</td><td align="char" char="(" rowspan="1" colspan="1">1 (4.76)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Lung</td><td align="char" char="(" rowspan="1" colspan="1">21 (18.92)</td><td align="char" char="(" rowspan="1" colspan="1">14 (41.18)</td><td align="char" char="(" rowspan="1" colspan="1">7 (12.5)</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">&#8195;Brain</td><td align="char" char="(" rowspan="1" colspan="1">3 (2.7)</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="char" char="(" rowspan="1" colspan="1">3 (14.29)</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>Abbreviation: vGCT, viable germ cell tumor.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Four Model Performances for Radiomics Feature Selection</title><p>Among the ML models, CB showed the highest AUC values on both the training and test sets. The CB performance metrics are presented in Table <xref rid="tbl2" ref-type="table">2</xref>, while the performance metrics for the other ML models are included in the supplementary section (Data Supplement, Tables S1 and S2) with the miRNAs-only model performance (Data Supplement, Tables S3 and S4, and Figs S2 and S3).</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>TABLE 2.</label><caption><p>The Performance of the CatBoost Model on the Training and Test Sets Across All Data Sets</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" colspan="1">Performance Metric</th><th colspan="2" align="center" rowspan="1">R</th><th colspan="2" align="center" rowspan="1">R + 371</th><th colspan="2" align="center" rowspan="1">R + 375</th><th colspan="2" align="center" rowspan="1">R + 371 + 375</th></tr><tr><th align="center" rowspan="1" colspan="1">Training</th><th align="center" rowspan="1" colspan="1">Test</th><th align="center" rowspan="1" colspan="1">Training</th><th align="center" rowspan="1" colspan="1">Test</th><th align="center" rowspan="1" colspan="1">Training</th><th align="center" rowspan="1" colspan="1">Test</th><th align="center" rowspan="1" colspan="1">Training</th><th align="center" rowspan="1" colspan="1">Test</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">AUC</td><td align="char" char="(" rowspan="1" colspan="1">0.89 (0.79-0.99)</td><td align="char" char="(" rowspan="1" colspan="1">0.81 (0.65-0.98)</td><td align="char" char="(" rowspan="1" colspan="1">0.91 (0.84-0.97)</td><td align="char" char="(" rowspan="1" colspan="1">0.81 (0.66-0.96)</td><td align="char" char="(" rowspan="1" colspan="1">0.95 (0.87-1.00)</td><td align="char" char="(" rowspan="1" colspan="1">0.82 (0.66-0.97)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.96</bold> (0.88-1.00)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.83</bold> (0.68-0.98)</td></tr><tr><td rowspan="1" colspan="1">Sensitivity</td><td align="char" char="(" rowspan="1" colspan="1">0.89 (0.78-0.99)</td><td align="char" char="(" rowspan="1" colspan="1">0.76 (0.55-0.98)</td><td align="char" char="(" rowspan="1" colspan="1">0.9 (0.76-0.99)</td><td align="char" char="(" rowspan="1" colspan="1">0.82 (0.63-1.0)</td><td align="char" char="(" rowspan="1" colspan="1">0.78 (0.65-0.94)</td><td align="char" char="(" rowspan="1" colspan="1">0.71 (0.53-0.87)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.88</bold> (0.74-0.98)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.71</bold> (0.57-0.89)</td></tr><tr><td rowspan="1" colspan="1">Specificity</td><td align="char" char="(" rowspan="1" colspan="1">0.79 (0.70-0.88)</td><td align="char" char="(" rowspan="1" colspan="1">0.65 (0.42-0.87)</td><td align="char" char="(" rowspan="1" colspan="1">0.52 (0.35-0.79)</td><td align="char" char="(" rowspan="1" colspan="1">0.47 (0.24-0.71)</td><td align="char" char="(" rowspan="1" colspan="1">0.92 (0.84-1.0)</td><td align="char" char="(" rowspan="1" colspan="1">0.65 (0.49-0.84)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.93</bold> (0.88-1.0)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.76</bold> (0.68-0.93)</td></tr><tr><td rowspan="1" colspan="1">NPV</td><td align="char" char="(" rowspan="1" colspan="1">0.86 (0.79-0.95)</td><td align="char" char="(" rowspan="1" colspan="1">0.73 (0.5-0.97)</td><td align="char" char="(" rowspan="1" colspan="1">0.84 (0.71-0.96)</td><td align="char" char="(" rowspan="1" colspan="1">0.73 (0.55-0.87)</td><td align="char" char="(" rowspan="1" colspan="1">0.81 (0.69-0.98)</td><td align="char" char="(" rowspan="1" colspan="1">0.69 (0.53-0.85)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.9</bold> (0.78-1.0)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.72</bold> (0.61-0.86)</td></tr><tr><td rowspan="1" colspan="1">PPV</td><td align="char" char="(" rowspan="1" colspan="1">0.85 (0.80-0.94)</td><td align="char" char="(" rowspan="1" colspan="1">0.68 (0.47-0.89)</td><td align="char" char="(" rowspan="1" colspan="1">0.69 (0.48-0.83)</td><td align="char" char="(" rowspan="1" colspan="1">0.61 (0.49-0.81)</td><td align="char" char="(" rowspan="1" colspan="1">0.92 (0.84-1.0)</td><td align="char" char="(" rowspan="1" colspan="1">0.67 (0.5-0.79)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.93</bold> (0.89-1.0)</td><td align="char" char="(" rowspan="1" colspan="1"><bold>0.75</bold> (0.67-0.91)</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>NOTE. The metrics reported include AUC, sensitivity, specificity, NPV, and PPV, presented as means with 95% CI. Bolded values indicate performance metrics for the R + 371 + 375 combination group in both the training and test sets.</p></fn><fn fn-type="abbr"><p>Abbreviations: NPV, negative predictive value; PPV, positive predictive value.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>CB Model on R-Only Data Set</title><p>CB exhibited the highest discriminatory ability between teratoma and nonteratoma samples, maintaining consistently superior AUC values on both the training (0.89 [95% CI, 0.79 to 0.99]) and test sets (0.81 [95% CI, 0.65 to 0.98]). Regarding additional performance metrics, again the CB model demonstrated a high SN of 0.89 (95% CI, 0.78 to 0.99) and SP of 0.79 (95% CI, 0.70 to 0.88) on the training set. Moreover, the NPV and PPV were also strong at 0.86 (95% CI, 0.79 to 0.95) and 0.85 (95% CI, 0.80 to 0.94), respectively, indicating robust overall predictive capabilities. However, when evaluated on the test set, all metrics exhibited a mild while expected decline, with SN decreasing to 0.76, SP to 0.65, NPV to 0.73, and PPV to 0.68.</p></sec><sec><title>Combination of R With miR371 and miR375 (R + 371 + 375)</title><p>An improvement in AUC was observed from R (0.89 in training; 0.81 in testing) to R + 371 + 375 (0.96 [95% CI, 0.88 to 1.0], in training; 0.83 [95% CI, 0.68 to 0.98], in testing) for predicting teratoma histology, indicating an enhanced overall discriminative ability. Although SN remained relatively consistent across models, the R + 371 + 375 data set demonstrated superior SP performance (0.93 in training and 0.76 in testing). Both NPV and PPV improved from R to R + 371 + 375, with the latter achieving the highest test PPV of 0.75 (Table <xref rid="tbl2" ref-type="table">2</xref> and Fig <xref rid="fig3" ref-type="fig">3</xref>).</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>FIG 3.</label><caption><p>ROC curves of CB radiomics and miRNAs across (A) training and (B) test sets. CB, CatBoost; R, radiomics-only; R + 371, radiomics + miR371; R + 375, radiomics + miR375; R + 371 + 375, radiomics + both miR371 and 375; ROC, receiver operating characteristic.</p></caption><graphic position="float" orientation="portrait" xlink:href="cci-9-e2500105-g003.jpg"/></fig><p>Overall, despite each model exhibiting distinct strengths and weaknesses, R + 371 + 375 emerged as the most balanced and improved performer. The combined CB model maintained high SN (0.88 in training and 0.71 in testing) while achieving the highest SP (0.93 in training and 0.76 in testing). It also exhibited the best NPV (0.90 in training and 0.72 in testing) and PPV (0.93 in training and 0.75 in testing).</p></sec><sec><title>Clinical Factors and R and microRNAs to Predict Teratoma</title><p>Known clinical factors associated with teratoma in the residual disease were tested to predict teratoma in this study. Univariate analysis showed that prechemotherapy AFP levels (odds ratio [OR], 1.0, <italic toggle="yes">P</italic> = .01), &#946;-hCG levels (OR, 0.99, <italic toggle="yes">P</italic> = .01), presence of teratoma in the primary (OR, 2.75, <italic toggle="yes">P</italic> = .01), and metastatic lesion being lymph node (OR, 3.13, <italic toggle="yes">P</italic> = .02) were statistically significant. However, in the multivariate analysis, the combination of R and miRNAs (radiomics signature) was the strongest predictor in both the training and test settings (<italic toggle="yes">P</italic> &lt; .0001 and <italic toggle="yes">P</italic> = .02, respectively; Table <xref rid="tbl3" ref-type="table">3</xref>).</p><table-wrap position="float" id="tbl3" orientation="portrait"><label>TABLE 3.</label><caption><p>Univariate and Multivariate Analyses of Predictive Factors </p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1">Feature</th><th align="center" rowspan="1" colspan="1">Univariate Analysis (full data set)<break/>Logistic Regression <italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">Multivariate Analysis (training set)</th><th align="center" rowspan="1" colspan="1">Multivariate Analysis (test set)</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Prechemotherapy AFP (&#181;g/L)</td><td rowspan="1" colspan="1">OR, 1.0003 (95% CI, 1.00004 to 1.00068), <italic toggle="yes">P</italic> = .01</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> = .22</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Prechemotherapy &#946;-hCG: (IU/L)</td><td rowspan="1" colspan="1">OR, 0.99 (95% CI, 0.99 to 0.99), <italic toggle="yes">P</italic> = .01</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> = .09</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Teratoma in initial pathology</td><td rowspan="1" colspan="1">OR, 2.75 (95% CI, 1.28 to 6.10), <italic toggle="yes">P</italic> = .01</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> = .38</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Primary lesion being lymph node</td><td rowspan="1" colspan="1">OR, 3.13 (95% CI, 1.22 to 8.81), <italic toggle="yes">P</italic> = .02</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> = .93</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Radiomics signature (R + miRNAs)</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">
<bold><italic toggle="yes">P</italic> &lt; .0001</bold>
</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Model performance</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">
<bold><italic toggle="yes">P</italic> &lt; .0001</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold><italic toggle="yes">P</italic> = .02</bold>
</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>NOTE. Significant predictors identified in the univariate analysis were AFP levels (<italic toggle="yes">P</italic> = .01), &#946;-hCG levels (<italic toggle="yes">P</italic> = .01), presence of teratoma in the primary (<italic toggle="yes">P</italic> = .01), and metastatic lymph node lesions (<italic toggle="yes">P</italic> = .02). The multivariate analysis incorporated these clinical features and the radiomics signature (radiomics features and miRNA expression levels). The radiomics signature was the strongest predictor with <italic toggle="yes">P</italic> values &lt; .0001 and .02. Bolded values highlight the performance of the radiomics signature in the multivariate analysis, as well as the model performances in the training and test sets.</p></fn><fn fn-type="abbr"><p>Abbreviations: AFP, alpha-fetoprotein; &#946;-hCG, beta-human chorionic gonadotropin; NA, not applicable; OR, odds ratio.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The most significant finding of this study is that ML models integrating radiomics features from CT images and miR371 and miR375 obtained before surgical resection can distinguish teratoma from nonteratoma histology in patients with mNSGCT presenting postchemotherapy residual disease (AUC of 0.96 in training and 0.83 in testing [95% CI, 0.68 to 0.98]). The proposed methodology can potentially improve treatment precision by reserving surgery for patients with residual teratoma or, in selected cases with vGCTs, sparing unnecessary surgery for patients with benign histology.</p><p>Predicting retroperitoneal histology of postchemotherapy disease in GCT has gained attention since the 90s and has mainly consisted of using clinical factors to predict residual disease histologies. Steyerberg et al<sup><xref rid="b38" ref-type="bibr">38</xref></sup> developed a clinical model with the parameters post-treatment residual mass size, mass size change during chemotherapy, prechemotherapy tumor marker levels, and the teratoma histology in the primary that can help predict residual disease histology. Subsequently, Vergouwe et al pioneered the field's predictive model to distinguish between postchemotherapy necrosis/fibrosis and vGCT or teratoma with achieved AUC values ranging from 0.77 to 0.84.<sup><xref rid="b39" ref-type="bibr">39</xref></sup> Clinical factors, however, have very limited value in identifying teratoma.<sup><xref rid="b40" ref-type="bibr">40</xref></sup></p><p>Recent studies suggest that circulating miRNAs can help identify residual disease in testicular cancer. The miR371, expressed by vGCT, is inaccurate in detecting teratoma, presenting a gap in its clinical applications. Attempts to address this gap with miR375 have shown limited value. As described by Nappi et al,<sup><xref rid="b30" ref-type="bibr">30</xref></sup> the combination of plasma miR371 and miR375 has an AUC of 0.77 in predicting residual teratoma, limiting its clinical utility.</p><p>In current clinical practice, only a small number of patients present residual active malignancy after chemotherapy.<sup><xref rid="b41" ref-type="bibr">41</xref></sup> These patients are easily identified by either standard serum tumor markers or miR371, which is not detectable in teratoma.<sup><xref rid="b37" ref-type="bibr">37</xref>,<xref rid="b42" ref-type="bibr">42</xref>,<xref rid="b43" ref-type="bibr">43</xref></sup> Thus, identifying teratoma is the primary unmet clinical need in managing postchemotherapy residual disease in mNSGCT. Building on this background, we hypothesize that integrating radiomics with miR371 and miR375 may improve the accuracy of detecting residual teratoma.</p><p>Model classifiers such as GB and SVM have been previously applied to testis cancer to evaluate radiomics prediction of malignant versus benign histologies. Baessler et al<sup><xref rid="b22" ref-type="bibr">22</xref></sup> developed a CT radiomics&#8211;based ML classifier to predict the histopathology of lymph nodes (eg, benign&#8212;necrosis/fibrosis, or malignant&#8211;vGCT and/or teratoma) after postchemotherapy RPLN dissection. They showed that the GB model performed well in predicting malignancy (AUC: 0.81, SN: 88%, and SP: 72%). The SVM classifier had a discriminative accuracy of 72% for differentiating between vGCT/teratoma and fibrosis (AUC: 0.74, SN: 56.2%, SP of 81.9%).<sup><xref rid="b44" ref-type="bibr">44</xref></sup> The model's discriminative accuracy improved from 72% to 88% when combined with clinical predictors.</p><p>CB has not been used to predict the histology of residual masses in testis cancer. In our study, CB integrating miR371 and miR375 demonstrated superior accuracy, with an AUC of 0.83 (95% CI, 0.68 to 0.98), SN of 0.71, and SP of 0.76. Moreover, the combination of CB radiomics and miRNAs independently predicted teratoma, while the clinical parameters did not demonstrate the ability to predict teratoma in the multivariate analysis.</p><p>Our observations were recently confirmed by Li et al. In this study, the combination of miR371, miR375, and radiomics achieved an AUC of 0.86 (95% CI, 0.72 to 1.0) for predicting teratoma histology in residual RPLNs. They also reported an AUC of 0.64 (95% CI, 0.41 to 0.87) for predicting vGCT and 0.78 (95% CI, 0.63 to 0.93) for predicting necrosis.<sup><xref rid="b45" ref-type="bibr">45</xref></sup> Of note, this study was only conducted using RPLN residual lesions and the models were not constructed to detect teratoma specifically.</p><p>Overall, integrated CT radiomics and circulating miRNA modeling is a new strategy that has not been previously explored to specifically detect residual teratoma. The idea of combining features from different evaluation models results in a multidimensional assessment of the residual tissue, which has the potential to provide better predictive ability. Our study distinguishes itself from previous research that primarily focused on radiomic features in RPLNs. It incorporates diverse features (miRNAs and radiomic features) and lesion locations, reflecting routine clinical practice. Finally, our multivariate model, combining radiomics signature (including radiomics features and miRNAs) and clinical parameters, highlights the superior predictive power of the radiomics signature, indicating that imaging features captured by radiomics outperform those provided by clinical parameters. An important point is that, despite their univariate associations, clinical factors lost their significance in the multivariate analysis. The potential reasons for that could be radiomic features extracted from postchemotherapy imaging, which may encompass features from markers of tumor burden, histology, and some other relevant features, absorbing the contribution of clinical variables. Additionally, the temporal proximity of radiomics data may provide more accurate predictions than baseline clinical information.</p><p>The retrospective design and limited patient cohort may affect the generalizability of our findings. Despite improvements in prediction capability, the inconsistent results with various radiomics models from the literature indicate the need for improvement in modeling strategies and highlight the challenges these models face with different data sets and histologies.</p><p>Fully automated segmentation tools may also be critical for improving model robustness and generalizability since the current methodology is operator-dependent. Additionally, advanced ensemble models could leverage the strengths of different ML models to enhance overall discrimination power.<sup><xref rid="b46" ref-type="bibr">46</xref>,<xref rid="b47" ref-type="bibr">47</xref></sup> Our findings underscore both the benefits and challenges associated with the integrated approaches incorporating both biomarker and radiomics, particularly highlighting the significant role of multiomics data integration with radiomic features in enhancing predictive accuracy. Although our study focuses on nongenomic data, integrating genomic features into the proposed models may offer detailed insights into the biological mechanism driving histological subtypes and their imaging correlates. Radiogenomics is an emerging field that combines radiomics and genomics features to overcome both approaches' shortcomings and enhance results. To date, there have been several reports on various cancers, including glioma, breast cancer, colorectal cancer, and clear cell carcinoma, reporting moderate to strong success with radiogenomics approaches detecting particular mutation or methylation patterns.<sup><xref rid="b48" ref-type="bibr">48</xref>,<xref rid="b49" ref-type="bibr">49</xref></sup> Testicular cancer histological subtypes reveal genomic heterogeneities such as <italic toggle="yes">KIT</italic> and <italic toggle="yes">KRAS</italic> mutations in seminoma and chromosomal instability in teratomas, possibly influencing miRNA expression and imaging features in specific ways. Benign lesions may also reflect genomic scarring after treatment or epigenetic silencing.<sup><xref rid="b50" ref-type="bibr">50</xref></sup> As such, linking radiomics features, miRNA expression patterns, and genomic features might better help with histology identification, which is an area for further investigation. However, it is also important to consider that overfitting remains a key concern when implementing multidimensional data.</p><p>Another caveat of almost all available data in the literature integrating biomarkers with radiomics is the possible limitations of building a classifier on the basis of multiple ROIs from the same patient with discordant lesions. Although the radiomics features are ROI-specific, miRNAs are lesion-specific and may pose limitations for data interpretation. In our cohort, there were no patients with discordant lesions (different lesion histology in the same patient). As such, this was not an issue affecting our analysis. However, multiple samples from the same patient still may compromise the data set's independence, introducing bias. With our study's relatively limited patient cohort, these factors may affect the generalizability of the findings. Therefore, collaboration is crucial to overcoming the limited sample size, possibly with independent patient samples. Despite all the limitations, promising findings reported here may provide a background for a follow-up prospective multicenter validation study. Moreover, in the era of an AI reproducibility crisis, where papers are published but cannot be reproduced, more elaborate descriptions of method specifics, radiomics features, ML details, and GitHub model sharing are needed.<sup><xref rid="b51" ref-type="bibr">51</xref>-<xref rid="b53" ref-type="bibr">53</xref></sup> For the current paper, the complete code is publicly available at GitHub.<sup><xref rid="b54" ref-type="bibr">54</xref></sup></p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>The authors acknowledge support from the BC Cancer Medical Imaging Core (CanMIC).</p></ack><fn-group content-type="presented-at"><title>PRIOR PRESENTATION</title><fn specific-use="presented-at" fn-type="presented-at"><p>Presented in part at the 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA, February 13&#8211;15, 2025 and the 2025 ASCO Annual Meeting, Chicago, IL, May 30&#8211;June 3, 2025.</p></fn></fn-group><fn-group content-type="supported-by"><title>SUPPORT</title><fn specific-use="supported-by" fn-type="supported-by"><p>Supported by the Michael Smith Health Research BC&#8212;Health Professional Investigator (HPI) Grant (Application ID: HPI&#8212;2020-0725) to Dr L.N.</p></fn></fn-group><fn-group><fn specific-use="equal" fn-type="equal"><label>*</label><p>R.Y. and L.N. contributed equally to this work.</p></fn></fn-group><sec sec-type="contributed"><title>AUTHOR CONTRIBUTIONS</title><p><bold>Conception and design:</bold> Guliz Ozgun, Neda Abdalvand, Nastaran Khazamipour, Craig Nichols, Ren Yuan, Lucia Nappi</p><p><bold>Financial support:</bold> Ren Yuan, Lucia Nappi</p><p><bold>Administrative support:</bold> Christian Kollmannsberger, Ren Yuan, Lucia Nappi</p><p><bold>Provision of study materials or patients:</bold> Bernhard J. Eigl, Christian Kollmannsberger, Corinne MauriceDror, Kim Chi, Lucia Nappi, Maryam Soleimani</p><p><bold>Collection and assembly of data:</bold> Guliz Ozgun, Neda Abdalvand, Gizem Ozcan, Ka Mun Nip, Nastaran Khazamipour, Christian Kollmannsberger, Ren Yuan, Lucia Nappi</p><p><bold>Data analysis and interpretation:</bold> All authors</p><p><bold>Manuscript writing:</bold> All authors</p><p><bold>Final approval of manuscript:</bold> All authors</p><p><bold>Accountable for all aspects of the work:</bold> All authors</p></sec><sec sec-type="COI-statement"><title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title><p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="https://ascopubs.org/cci/author-center" ext-link-type="uri">ascopubs.org/cci/author-center</ext-link>.</p><p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p><fn-group content-type="COI-statement"><fn id="con1" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Neda Abdalvand</bold>
</p><p><bold>Employment:</bold> BC Cancer Agency</p></fn><fn id="con2" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Arman Rahmim</bold>
</p><p><bold>Stock and Other Ownership Interests:</bold> Ascinta Technologies Inc</p></fn><fn id="con3" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Christian Kollmannsberger</bold>
</p><p><bold>Honoraria:</bold> Pfizer, Bristol Myers Squibb, Ipsen, Merck KGaA, Merck, Astellas Pharma, Janssen Oncology, Eisai, Bayer, Seagen, Novartis Canada Pharmaceuticals Inc</p><p><bold>Consulting or Advisory Role:</bold> Pfizer, Bristol Myers Squibb, Astellas Pharma, Ipsen, Eisai, Janssen, Merck KGaA, Merck, Gilead Sciences, Bayer, AAA/Endocyte/Novartis, Seagen, BioNTech SE</p><p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, Ipsen, Janssen Oncology, AAA Canada</p></fn><fn id="con4" specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Lucia Nappi</bold>
</p><p><bold>Honoraria:</bold> Pfizer, Ipsen, Bayer, Janssen, Tersera</p><p><bold>Consulting or Advisory Role:</bold> Bayer, Ipsen, Pfizer, Novartis, Eisai</p><p><bold>Research Funding:</bold> Bayer (Inst)</p><p><bold>Patents, Royalties, Other Intellectual Property:</bold> IVERMECTIN ANALOGUE COMPOUND THERAPEUTICS FOR HEAT SHOCK PROTEIN-27 (HSP27) INHIBITION, METHODS AND USES ASSOCIATED THEREWITH provisional number: 62/756,707</p><p><bold>Travel, Accommodations, Expenses:</bold> Pfizer</p><p>No other potential conflicts of interest were reported.</p></fn></fn-group></sec><notes><fn-group content-type="COI-statement"><fn specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Neda Abdalvand</bold>
</p><p><bold>Employment:</bold> BC Cancer Agency</p></fn><fn specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Arman Rahmim</bold>
</p><p><bold>Stock and Other Ownership Interests:</bold> Ascinta Technologies Inc</p></fn><fn specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Christian Kollmannsberger</bold>
</p><p><bold>Honoraria:</bold> Pfizer, Bristol Myers Squibb, Ipsen, Merck KGaA, Merck, Astellas Pharma, Janssen Oncology, Eisai, Bayer, Seagen, Novartis Canada Pharmaceuticals Inc</p><p><bold>Consulting or Advisory Role:</bold> Pfizer, Bristol Myers Squibb, Astellas Pharma, Ipsen, Eisai, Janssen, Merck KGaA, Merck, Gilead Sciences, Bayer, AAA/Endocyte/Novartis, Seagen, BioNTech SE</p><p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, Ipsen, Janssen Oncology, AAA Canada</p></fn><fn specific-use="COI-statement" fn-type="COI-statement"><p>
<bold>Lucia Nappi</bold>
</p><p><bold>Honoraria:</bold> Pfizer, Ipsen, Bayer, Janssen, Tersera</p><p><bold>Consulting or Advisory Role:</bold> Bayer, Ipsen, Pfizer, Novartis, Eisai</p><p><bold>Research Funding:</bold> Bayer (Inst)</p><p><bold>Patents, Royalties, Other Intellectual Property:</bold> IVERMECTIN ANALOGUE COMPOUND THERAPEUTICS FOR HEAT SHOCK PROTEIN-27 (HSP27) INHIBITION, METHODS AND USES ASSOCIATED THEREWITH provisional number: 62/756,707</p><p><bold>Travel, Accommodations, Expenses:</bold> Pfizer</p><p>No other potential conflicts of interest were reported.</p></fn></fn-group></notes><ref-list><title>REFERENCES</title><ref id="b1"><label>1.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>SEER Cancer Statistics Factsheets</collab></person-group>: <source>Testicular Cancer</source>. <publisher-loc>Bethesda, MD</publisher-loc>, <publisher-name>National Cancer Institute</publisher-name>, <year>2020</year></mixed-citation></ref><ref id="b2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanmugalingam</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Soultati</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>: <article-title>Global incidence and outcome of testicular cancer</article-title>. <source>Clin Epidemiol</source><volume>5</volume>:<fpage>417</fpage>-<lpage>427</lpage>, <year>2013</year><pub-id pub-id-type="pmid">24204171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CLEP.S34430</pub-id><pub-id pub-id-type="pmcid">PMC3804606</pub-id></mixed-citation></ref><ref id="b3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moch</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Cubilla</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Humphrey</surname><given-names>PA</given-names></name>, <etal>et al</etal></person-group>: <article-title>The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours</article-title>. <source>Eur Urol</source><volume>70</volume>:<fpage>93</fpage>-<lpage>105</lpage>, <year>2016</year><pub-id pub-id-type="pmid">26935559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2016.02.029</pub-id></mixed-citation></ref><ref id="b4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umbreit</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Joon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Westerman</surname><given-names>ME</given-names></name>, <etal>et al</etal></person-group>: <article-title>Origin of somatic transformation in germ cell tumor of testis (TGCT): Role of differentiation versus dedifferentiation in a mature teratoma</article-title>. <source>J Clin Oncol</source><volume>38</volume>, <year>2020</year><comment>(suppl 6; abstr 410)</comment></mixed-citation></ref><ref id="b5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoenhals</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kassambara</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Vos</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>Embryonic stem cell markers expression in cancers</article-title>. <source>Biochem Biophys Res Commun</source><volume>383</volume>:<fpage>157</fpage>-<lpage>162</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19268426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2009.02.156</pub-id></mixed-citation></ref><ref id="b6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nestler</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kremer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>von Brandenstein</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>: <article-title>Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue</article-title>. <source>Cancer</source><volume>129</volume>:<fpage>634</fpage>-<lpage>642</lpage>, <year>2023</year><pub-id pub-id-type="pmid">36504384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.34571</pub-id></mixed-citation></ref><ref id="b7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paffenholz</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pfister</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Busch</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>Management of growing teratoma syndrome (GTS): Results of the German Testicular Cancer Study Group</article-title>. <source>J Clin Oncol</source><volume>36</volume>, <year>2018</year><comment>(suppl 6; abstr 566)</comment></mixed-citation></ref><ref id="b8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Amsterdam</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Prieto</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group>: <article-title>Teratoma with malignant transformation: Diverse malignant histologies arising in men with germ cell tumors</article-title>. <source>J Urol</source><volume>159</volume>:<fpage>133</fpage>-<lpage>138</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9400455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-5347(01)64035-7</pub-id></mixed-citation></ref><ref id="b9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logothetis</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Samuels</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Trindade</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>The growing teratoma syndrome</article-title>. <source>Cancer</source><volume>50</volume>:<fpage>1629</fpage>-<lpage>1635</lpage>, <year>1982</year><pub-id pub-id-type="pmid">6288220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19821015)50:8&lt;1629::aid-cncr2820500828&gt;3.0.co;2-1</pub-id></mixed-citation></ref><ref id="b10"><label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>EAU Guidelines</collab></person-group>: <source>Presented at the EAU Annual Congress Paris</source>. <comment>EAU Guidelines on Testicular cancer, Section 6.3.2.2 Non-seminoma, 2024, pp 27</comment></mixed-citation></ref><ref id="b11"><label>11.</label><mixed-citation publication-type="book"><source>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&#174;) for Testicular Cancer V.1.2025</source>. <publisher-name>National Comprehensive Cancer Network,</publisher-name><year>2025</year></mixed-citation></ref><ref id="b12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brenner</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Hartmann</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>: <article-title>[18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: Results of the German multicentre trial</article-title>. <source>Ann Oncol</source><volume>19</volume>:<fpage>1619</fpage>-<lpage>1623</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18453520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdn170</pub-id></mixed-citation></ref><ref id="b13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huddart</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>O'Doherty</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Padhani</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: Preliminary report of MRC trial TE22--the NCRI Testis Tumour Clinical Study Group</article-title>. <source>J Clin Oncol</source><volume>25</volume>:<fpage>3090</fpage>-<lpage>3095</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17634488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2006.09.3831</pub-id></mixed-citation></ref><ref id="b14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillies</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Kinahan</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Hricak</surname><given-names>H</given-names></name></person-group>: <article-title>Radiomics: Images are more than pictures, they are data</article-title>. <source>Radiology</source><volume>278</volume>:<fpage>563</fpage>-<lpage>577</lpage>, <year>2016</year><pub-id pub-id-type="pmid">26579733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2015151169</pub-id><pub-id pub-id-type="pmcid">PMC4734157</pub-id></mixed-citation></ref><ref id="b15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosny</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Parmar</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Quackenbush</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>Artificial intelligence in radiology</article-title>. <source>Nat Rev Cancer</source><volume>18</volume>:<fpage>500</fpage>-<lpage>510</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29777175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-018-0016-5</pub-id><pub-id pub-id-type="pmcid">PMC6268174</pub-id></mixed-citation></ref><ref id="b16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aerts</surname><given-names>HJWL</given-names></name>, <name name-style="western"><surname>Velazquez</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Leijenaar</surname><given-names>RTH</given-names></name>, <etal>et al</etal></person-group>: <article-title>Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach</article-title>. <source>Nat Commun</source><volume>5</volume>:<fpage>4006</fpage>, <year>2014</year><pub-id pub-id-type="pmid">24892406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms5006</pub-id><pub-id pub-id-type="pmcid">PMC4059926</pub-id></mixed-citation></ref><ref id="b17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>: <article-title>Machine learning-based Radiomics analysis for differentiation degree and lymphatic node metastasis of extrahepatic cholangiocarcinoma</article-title>. <source>BMC Cancer</source><volume>21</volume>:<fpage>1268</fpage>, <year>2021</year><pub-id pub-id-type="pmid">34819043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-021-08947-6</pub-id><pub-id pub-id-type="pmcid">PMC8611922</pub-id></mixed-citation></ref><ref id="b18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bera</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Braman</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Predicting cancer outcomes with radiomics and artificial intelligence in radiology</article-title>. <source>Nat Rev Clin Oncol</source><volume>19</volume>:<fpage>132</fpage>-<lpage>146</lpage>, <year>2022</year><pub-id pub-id-type="pmid">34663898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00560-7</pub-id><pub-id pub-id-type="pmcid">PMC9034765</pub-id></mixed-citation></ref><ref id="b19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Huh</surname><given-names>Y-M</given-names></name>, <etal>et al</etal></person-group>: <article-title>A radiomics-based model for predicting prognosis of locally advanced gastric cancer in the preoperative setting</article-title>. <source>Sci Rep</source><volume>11</volume>:<fpage>1879</fpage>, <year>2021</year><pub-id pub-id-type="pmid">33479398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-81408-z</pub-id><pub-id pub-id-type="pmcid">PMC7820605</pub-id></mixed-citation></ref><ref id="b20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>A radiomics-based model for prediction of lymph node metastasis in gastric cancer</article-title>. <source>Eur J Radiol</source><volume>129</volume>:<fpage>109069</fpage>, <year>2020</year><pub-id pub-id-type="pmid">32464581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejrad.2020.109069</pub-id></mixed-citation></ref><ref id="b21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Abdalvand</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mahdavi</surname><given-names>SR</given-names></name>, <etal>et al</etal></person-group>: <article-title>Magnetic resonance image radiomic reproducibility: The impact of preprocessing on extracted features from gross and high-risk clinical tumor volumes in cervical cancer patients before brachytherapy</article-title>. <source>J Med Signals Sens</source><volume>14</volume>:<fpage>23</fpage>, <year>2024</year><pub-id pub-id-type="pmid">39234589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/jmss.jmss_57_22</pub-id><pub-id pub-id-type="pmcid">PMC11373798</pub-id></mixed-citation></ref><ref id="b22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baessler</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Nestler</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Pinto Dos Santos</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>: <article-title>Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection</article-title>. <source>Eur Radiol</source><volume>30</volume>:<fpage>2334</fpage>-<lpage>2345</lpage>, <year>2020</year><pub-id pub-id-type="pmid">31828413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-019-06495-z</pub-id></mixed-citation></ref><ref id="b23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scavuzzo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Crescio</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rodr&#237;guez</surname><given-names>PF</given-names></name>, <etal>et al</etal></person-group>: <article-title>MP33-16 radiomics model to predict teratoma in metastatic non-seminomatous testicular germ cell tumors</article-title>. <source>J Urol</source><volume>209</volume>:<fpage>e456</fpage>, <year>2023</year></mixed-citation></ref><ref id="b24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venishetty</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xi</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>: <article-title>Testicular radiomics to predict pathology at time of postchemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell tumor</article-title>. <source>Clin Genitourin Cancer</source><volume>22</volume>:<fpage>33</fpage>-<lpage>37</lpage>, <year>2024</year><pub-id pub-id-type="pmid">37468341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clgc.2023.07.004</pub-id></mixed-citation></ref><ref id="b25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le&#227;o</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Albersen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Looijenga</surname><given-names>LHJ</given-names></name>, <etal>et al</etal></person-group>: <article-title>Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumours: A systematic review</article-title>. <source>Eur Urol</source><volume>80</volume>:<fpage>456</fpage>-<lpage>466</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34175151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2021.06.006</pub-id></mixed-citation></ref><ref id="b26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belge</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Dumlupinar</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Nestler</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>: <article-title>Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study</article-title>. <source>Clin Cancer Res</source><volume>30</volume>:<fpage>404</fpage>-<lpage>412</lpage>, <year>2024</year><pub-id pub-id-type="pmid">37967143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-23-0730</pub-id><pub-id pub-id-type="pmcid">PMC10792362</pub-id></mixed-citation></ref><ref id="b27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dieckmann</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Radtke</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Geczi</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>: <article-title>Serum levels of MicroRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: Results of a prospective multicentric study</article-title>. <source>J Clin Oncol</source><volume>37</volume>:<fpage>1412</fpage>-<lpage>1423</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30875280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.18.01480</pub-id><pub-id pub-id-type="pmcid">PMC6544462</pub-id></mixed-citation></ref><ref id="b28"><label>28.</label><mixed-citation publication-type="other"><comment>SWOG S1823: A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors. ClinicalTrials.gov Identifier: <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04435756">NCT04435756</ext-link></comment></mixed-citation></ref><ref id="b29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaikh</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bagrodia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Amatruda</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>AGCT1531: Evaluating the utility of circulating microRNA in the management of children, adolescents, and adults with malignant germ cell tumors</article-title>. <source>J Clin Oncol</source><volume>41</volume>, <year>2023</year><comment>(suppl 6; abstr TPS5104)</comment></mixed-citation></ref><ref id="b30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nappi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Thi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Adra</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>: <article-title>Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumors</article-title>. <source>Eur Urol</source><volume>79</volume>:<fpage>16</fpage>-<lpage>19</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33158661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2020.10.024</pub-id></mixed-citation></ref><ref id="b31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metcalf</surname><given-names>GAD</given-names></name></person-group>: <article-title>MicroRNAs: Circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances</article-title>. <source>Oncogene</source><volume>43</volume>:<fpage>2135</fpage>-<lpage>2142</lpage>, <year>2024</year><pub-id pub-id-type="pmid">38839942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-024-03076-3</pub-id><pub-id pub-id-type="pmcid">PMC11226400</pub-id></mixed-citation></ref><ref id="b32"><label>32.</label><mixed-citation publication-type="book"><collab>3D Slicer, version 5.6.1</collab>. <publisher-loc>Harvard Surgical Planning Laboratory</publisher-loc>. <ext-link xlink:href="https://www.slicer.org" ext-link-type="uri">https://www.slicer.org</ext-link></mixed-citation></ref><ref id="b33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamzam</surname><given-names>YF</given-names></name>, <name name-style="western"><surname>Saragih</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Herteno</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>Comparison of CatBoost and random forest methods for lung cancer classification using hyperparameter tuning bayesian optimization-based</article-title>. <source>J Electron Electromed Eng Med Inform</source><volume>6</volume>:<fpage>125</fpage>-<lpage>136</lpage>, <year>2024</year></mixed-citation></ref><ref id="b34"><label>34.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Baig</surname><given-names>PMM</given-names></name>, <name name-style="western"><surname>Wankhede</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Samritkar</surname><given-names>VM</given-names></name>, <etal>et al</etal></person-group>: <article-title>Performance comparison of CatBoost and random forest algorithms for breast cancer prediction: A literature review</article-title>. in <source>2023 3rd International Conference on Smart Generation Computing, Communication and Networking (SMART GENCON)</source>, <year>2023</year>, pp <fpage>1</fpage>-<lpage>6</lpage></mixed-citation></ref><ref id="b35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asghari Ilani</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kavei</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Moftakhar Tehran</surname><given-names>S</given-names></name></person-group>: <article-title>A comparative analysis of machine learning models for lung cancer prediction: From traditional algorithms to deep learning approaches, Preprints</article-title>. <year>2024</year></mixed-citation></ref><ref id="b36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdalvand</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sadeghi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mahdavi</surname><given-names>SR</given-names></name>, <etal>et al</etal></person-group>: <article-title>Brachytherapy outcome modeling in cervical cancer patients: A predictive machine learning study on patient-specific clinical, physical and dosimetric parameters</article-title>. <source>Brachytherapy</source><volume>21</volume>:<fpage>769</fpage>-<lpage>782</lpage>, <year>2022</year><pub-id pub-id-type="pmid">35933272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brachy.2022.06.007</pub-id></mixed-citation></ref><ref id="b37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nappi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Thi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lum</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Developing a highly specific biomarker for germ cell malignancies: Plasma miR371 expression across the germ cell malignancy spectrum</article-title>. <source>J Clin Oncol</source><volume>37</volume>:<fpage>3090</fpage>-<lpage>3098</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31553692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.18.02057</pub-id><pub-id pub-id-type="pmcid">PMC7351323</pub-id></mixed-citation></ref><ref id="b38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></name>, <name name-style="western"><surname>Keizer</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Foss&#229;</surname><given-names>SD</given-names></name>, <etal>et al</etal></person-group>: <article-title>Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups</article-title>. <source>J Clin Oncol</source><volume>13</volume>:<fpage>1177</fpage>-<lpage>1187</lpage>, <year>1995</year><pub-id pub-id-type="pmid">7537801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1995.13.5.1177</pub-id></mixed-citation></ref><ref id="b39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vergouwe</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></name>, <name name-style="western"><surname>Foster</surname><given-names>RS</given-names></name>, <etal>et al</etal></person-group>: <article-title>Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: A model update and multicentre validation with more than 1000 patients</article-title>. <source>Eur Urol</source><volume>51</volume>:<fpage>424</fpage>-<lpage>432</lpage>, <year>2007</year><pub-id pub-id-type="pmid">16911854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2006.06.047</pub-id></mixed-citation></ref><ref id="b40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></name>, <name name-style="western"><surname>Gerl</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Foss&#225;</surname><given-names>SD</given-names></name>, <etal>et al</etal></person-group>: <article-title>Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer</article-title>. <source>J Clin Oncol</source><volume>16</volume>:<fpage>269</fpage>-<lpage>274</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9440752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1998.16.1.269</pub-id></mixed-citation></ref><ref id="b41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fizazi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tjulandin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Salvioni</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy&#8211;results from an international study group</article-title>. <source>J Clin Oncol</source><volume>19</volume>:<fpage>2647</fpage>-<lpage>2657</lpage>, <year>2001</year><pub-id pub-id-type="pmid">11352956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2001.19.10.2647</pub-id></mixed-citation></ref><ref id="b42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le&#227;o</surname><given-names>R</given-names></name>, <name name-style="western"><surname>van Agthoven</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Figueiredo</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor</article-title>. <source>J Urol</source><volume>200</volume>:<fpage>126</fpage>-<lpage>135</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29474847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.juro.2018.02.068</pub-id></mixed-citation></ref><ref id="b43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Le&#227;o</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gillis</surname><given-names>AJM</given-names></name>, <etal>et al</etal></person-group>: <article-title>Utility of serum miR-371a-3p in predicting relapse on surveillance in patients with clinical stage I testicular germ cell cancer</article-title>. <source>Eur Urol Oncol</source><volume>4</volume>:<fpage>483</fpage>-<lpage>491</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33288479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euo.2020.11.004</pub-id></mixed-citation></ref><ref id="b44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dufort</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Halankar</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>Applying radiomics to predict pathology of postchemotherapy retroperitoneal nodal masses in germ cell tumors</article-title>. <source>JCO Clin Cancer Inform</source><ext-link xlink:href="https://ascopubs.org/doi/full/10.1200/CCI.18.00004" ext-link-type="uri">10.1200/CCI.18.00004</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/CCI.18.00004</pub-id><pub-id pub-id-type="pmcid">PMC6874033</pub-id><pub-id pub-id-type="pmid">30652572</pub-id></mixed-citation></ref><ref id="b45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name>, <etal>et al</etal></person-group>: <article-title>A predictive system comprising serum microRNAs and radiomics for residual retroperitoneal masses in metastatic nonseminomatous germ cell tumors</article-title>. <source>Cell Rep Med</source><volume>5</volume>:<fpage>101843</fpage>, <year>2024</year><pub-id pub-id-type="pmid">39672156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2024.101843</pub-id><pub-id pub-id-type="pmcid">PMC11722113</pub-id></mixed-citation></ref><ref id="b46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahajan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Uddin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hajati</surname><given-names>F</given-names></name>, <etal>et al</etal></person-group>: <article-title>Ensemble learning for disease prediction: A review</article-title>. <source>Healthcare (Basel)</source><volume>11</volume>:<fpage>1808</fpage>, <year>2023</year><pub-id pub-id-type="pmid">37372925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/healthcare11121808</pub-id><pub-id pub-id-type="pmcid">PMC10298658</pub-id></mixed-citation></ref><ref id="b47"><label>47.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Akinbo</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Daramola</surname><given-names>OA</given-names></name></person-group>: <article-title>Ensemble machine learning algorithms for prediction and classification of medical images</article-title>, in <person-group person-group-type="editor"><name name-style="western"><surname>Sen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mehtab</surname><given-names>S</given-names></name></person-group> (eds): <source>Machine Learning&#8212;Algorithms, Models and Applications</source>. <publisher-loc>Rijeka, Croatia</publisher-loc>, <publisher-name>IntechOpen</publisher-name>, <year>2021</year></mixed-citation></ref><ref id="b48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shui</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X</given-names></name>, <etal>et al</etal></person-group>: <article-title>The Era of radiogenomics in precision medicine: An emerging approach to support diagnosis, treatment decisions, and prognostication in Oncology</article-title>. <source>Front Oncol</source><volume>10</volume>:<fpage>570465</fpage>, <year>2020</year><pub-id pub-id-type="pmid">33575207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.570465</pub-id><pub-id pub-id-type="pmcid">PMC7870863</pub-id></mixed-citation></ref><ref id="b49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>: <article-title>Radiogenomics: A key component of precision cancer medicine</article-title>. <source>Br J Cancer</source><volume>129</volume>:<fpage>741</fpage>-<lpage>753</lpage>, <year>2023</year><pub-id pub-id-type="pmid">37414827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-023-02317-8</pub-id><pub-id pub-id-type="pmcid">PMC10449908</pub-id></mixed-citation></ref><ref id="b50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loveday</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Litchfield</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Proszek</surname><given-names>PZ</given-names></name>, <etal>et al</etal></person-group>: <article-title>Genomic landscape of platinum resistant and sensitive testicular cancers</article-title>. <source>Nat Commun</source><volume>11</volume>:<fpage>2189</fpage>, <year>2020</year><pub-id pub-id-type="pmid">32366847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-15768-x</pub-id><pub-id pub-id-type="pmcid">PMC7198558</pub-id></mixed-citation></ref><ref id="b51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutson</surname><given-names>M</given-names></name></person-group>: <article-title>Artificial intelligence faces reproducibility crisis</article-title>. <source>Science</source><volume>359</volume>:<fpage>725</fpage>-<lpage>726</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29449469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.359.6377.725</pub-id></mixed-citation></ref><ref id="b52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>H</given-names></name></person-group>: <article-title>Challenges of reproducible AI in biomedical data science</article-title>. <source>BMC Med Genomics</source><volume>18</volume>:<fpage>8</fpage>, <year>2025</year><comment>(suppl 1)</comment><pub-id pub-id-type="pmid">39794788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12920-024-02072-6</pub-id><pub-id pub-id-type="pmcid">PMC11724458</pub-id></mixed-citation></ref><ref id="b53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciobanu-Caraus</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Aicher</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kernbach</surname><given-names>JM</given-names></name>, <etal>et al</etal></person-group>: <article-title>A critical moment in machine learning in medicine: On reproducible and interpretable learning</article-title>. <source>Acta Neurochir (Wien)</source><volume>166</volume>:<fpage>14</fpage>, <year>2024</year><pub-id pub-id-type="pmid">38227273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00701-024-05892-8</pub-id><pub-id pub-id-type="pmcid">PMC10791964</pub-id></mixed-citation></ref><ref id="b54"><label>54.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Abdalvand</surname><given-names>N</given-names></name></person-group>: <collab>GCT_Histology_Classification</collab>. <article-title>GitHub repository</article-title>. <ext-link xlink:href="https://github.com/NedaAbdalvand/GCT_Histology_Classification" ext-link-type="uri">https://github.com/NedaAbdalvand/GCT_Histology_Classification</ext-link></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>